# Safety, Tolerability and Efficacy of VUM02 Injection in Treatment of Idiopathic Pulmonary Fibrosis (IPF)

> **NCT06230822** · PHASE1 · RECRUITING · sponsor: **Wuhan Optics Valley Vcanbiopharma Co., Ltd.** · enrollment: 9 (estimated)

## Conditions studied

- Idiopathic Pulmonary Fibrosis

## Interventions

- **DRUG:** VUM02 Injection

## Key facts

- **NCT ID:** NCT06230822
- **Lead sponsor:** Wuhan Optics Valley Vcanbiopharma Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-02
- **Primary completion:** 2025-01
- **Final completion:** 2026-12
- **Target enrollment:** 9 (ESTIMATED)
- **Last updated:** 2024-02-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06230822

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06230822, "Safety, Tolerability and Efficacy of VUM02 Injection in Treatment of Idiopathic Pulmonary Fibrosis (IPF)". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT06230822. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*